Ignyta Completes Merger and Announces License Agreement for the Development of Two Leading Tyrosine Kinase Inhibitors

04-11-2013 Business Wire HealthComments (0)

BiotechnologyIgnyta

Ignyta goes public via reverse merger and in licenses two leading kinase inhibitor precision medicines for oncology indications

Read more on Business Wire Health

Your Comments

Login to add a comment

There are no comments yet. Be the first and leave a response!

Back to top